| Sep 29, 2010
British scientists have found the first direct evidence that attention-deficit/hyperactivity disorder is a genetic disorder and say their research could eventually lead to better treatments for the condition.
Researchers who scanned the gene maps of more...
| Aug 28, 2011
| 7:37 AM
PARIS (Reuters) - An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market.
Although Eliquis will...
| Sep 26, 2011
| 8:30 PM
(Reuters) - Johnson & Johnson has told doctors it expects a limited supply of its Doxil cancer drug to become available within the next six weeks, but warned the amount would not be sufficient for all patients currently on waiting lists.
| Sep 7, 2011
| 9:21 AM
LONDON (Reuters) - Johnson & Johnson's prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.
| Aug 10, 2011
| 10:55 AM
LOS ANGELES (Reuters) - U.S. regulators are moving quickly with Roche's application for targeted melanoma drug vemurafenib, which could receive approval as early as this week, according to a source familiar with the situation.
A pivotal trial found...
| Nov 29, 2011
Night driving entails a whole host of challenges, not the least of which is the frequency with which that same sappy love song pops up on station after station.
Lovelorn call-in shows aside, driving in the dark poses very real dangers to your physical...
| Mar 30, 2011
| 10:23 AM
NEW YORK -- Johnson & Johnson said it was recalling more than 700,000 bottles or packages of Tylenol and other consumer medicines made at a now-closed plant, the latest in a litany of recalls by the company.
J&J's McNeil Consumer Healthcare unit recalled...
| Jun 12, 2011
| 8:02 PM
NEW YORK (KTLA) -- The number of drug shortages is at a record high, and the Food and Drug Administration is warning that they are getting even worse.
Fueling the problem are shortages of raw materials. Also, drugmakers are discontinuing older, and off-...
| Jun 15, 2011
| 3:57 AM
CHICAGO (Reuters) - New labeling rules for sunscreens should make it easier for U.S. consumers to choose products that will protect them from sunburn, skin cancer and premature aging.
The U.S. Food and Drug Administration ruled on Tuesday that sunscreens...
| Dec 9, 2010
| 3:29 PM
Johnson & Johnson is recalling several types of Rolaids in the U.S. because of reports of metal and wood particles in the products.
The products include Rolaids Extra Strength Softchews, Rolaids Extra Strength plus Gas Softchews, and Rolaids Multi-...
| Dec 10, 2010
| 11:29 AM
NEW YORK -- Johnson & Johnson on Thursday recalled several types of Rolaids antacids in the U.S. because of reports of metal and wood particles in the products.
The voluntary recall comes less than a month after the company issued another voluntary...